Moderna Inc (MRNA)

$122.50 1.36 (1.12%)

16:00 EDT MRNA Stock Quote Delayed 30 Minutes

7 Pharmaceutical Stocks With Exciting Plans for 2021

By Bret Kenwell, InvestorPlace Contributor Jan 13, 2021

Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case.

7 Great Speculations for 2021

Healthcare Stocks: How AI Is Helping in the Fight Against COVID-19

As Competition Rises, the Bull Case for Moderna Stock Is Beginning to Fade

Volume:

Previous Close -

Market Cap 46.92B

PE Ratio -7.82

EPS -15.66

Volume (Avg. Vol.) 1.81M

Day's Range $120.44 - $124.06

52-Week Range $62.55 - $170.47

Dividend & Yield N/A (N/A)

MRNA Stock Predictions, Articles, and Moderna Inc News

Moderna Is An Example of Why You Should Buy Systems, Not Drugs

By Dana Blankenhorn, InvestorPlace Contributor Jan 7, 2021

Moderna's vaccine for Covid-19 proves its operating system for creating new drugs works. That means more growth is ahead for MRNA stock.

Vaccine Backlog Raises New Questions About Moderna

By Josh Enomoto, InvestorPlace Contributor Jan 7, 2021

As one of the leaders in the Covid-19 vaccine race, Moderna’s success boosted MRNA stock. But with real-time obstacles coming into the picture, the narrative moving forward isn’t as exciting.

2020 In Review — 9 Great (And Not-So-Great) Calls

By Chris Lau, InvestorPlace Contributor Jan 6, 2021

Technology and biotech stocks brought in more winning picks than usual, thanks partly to the strong stock market. Here are some of my best calls.

The Opportunity May Just Be Getting Started For Moderna

By Chris Markoch, InvestorPlace Contributor Jan 6, 2021

If you’re interested in buying this dip in Moderna, it’s important to understand that you’re investing in mRNA technology more than MRNA stock.

7 Coronavirus Stocks to Buy to Make Mass Vaccination Possible

By Divya Premkumar, InvestorPlace Contributor Jan 5, 2021

The Covid-19 vaccine rally isn’t just limited to biotech firms. Here are the top coronavirus stocks that are making mass vaccination possible.

Grab Falling Moderna Shares as the Vaccine Rollout Goes Global

By Louis Navellier and the InvestorPlace Research Staff Jan 4, 2021

MRNA stock isn't under the radar any longer, but it is priced below where it ought to be as Covid-19 vaccines will remain in heavy demand.

Use Weakness in Moderna as Buying Opportunity

By Ian Cooper, InvestorPlace Contributor Jan 4, 2021

While vaccine stocks slipped on a “sell-the-news” reaction, there’s still plenty of opportunity to be found, including MRNA stock.

4 Top Stock Trades for Monday: AAPL, GLD, MRNA, CMI

By Bret Kenwell, InvestorPlace Contributor Dec 31, 2020

Apple, the gold ETF, Moderna and Cummins were our top stock trades as head into the first trading session of 2021. Let's look at the charts.

Moderna’s Share Price Continues to Lose Altitude

By Will Ashworth, InvestorPlace Contributor Dec 31, 2020

Moderna’s Covid-19 vaccine has finally made its way across the country. MRNA stock continues to lose altitude. Why is that?

Moderna Stock Is More Than The Covid-19 Vaccine

By Tom Taulli, InvestorPlace Contributor Dec 31, 2020

With the recent drop in MRNA stock, there looks like a nice opportunity for long-term investors.

Moderna Stock Is Worth Much More

By Mark R. Hake, CFA Dec 31, 2020

Moderna reaps the rewards of its Covid-19 vaccine, and MRNA stock is worth 57% to 172% more based on near-term and long-term earnings power.

Moderna Is a Great Investment Despite Short-Term Headwinds

By Divya Premkumar, InvestorPlace Contributor Dec 29, 2020

Following the FDA approval of its vaccine, MRNA stock is set to make some big gains on distribution deals across the globe.

Is Now a Good Time to Buy Moderna Stock?

By Chris Tyler, InvestorPlace Contributor Dec 29, 2020

MRNA stock has many of us breathing easier amid Covid-19, but Moderna investors aren't in that group just yet.

Here’s Why Moderna Stock Could Be the Stock of the Decade

By Dana Blankenhorn, InvestorPlace Contributor Dec 28, 2020

Moderna was able to develop what proved to ve a successful COVID-19 vaccine over a weekend, thanks to Messenger RNA technology it had been working on for a decade.